<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT922-9286</title>
	</head>
	<body>
		<main>
			<p>920508 FT  08 MAY 92 / International Company News: Chiron wins FDA approval for cancer drug CHIRON, the US biotechnology company, has received approval from the US Food and Drug Administration to market Interleukin-2, a long-awaited treatment for aggressive kidney cancer, writes Louise Kehoe in San Francisco. The approval marks the end of an eight-year struggle to bring to the US market what had widely been regarded as one of the most promising products of the US biotechnology industry. Interleukin-2 will be sold under the brand name Proleukin.</p>
		</main>
</body></html>
            